Related Experiment Video
Updated: Jan 17, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Nonhematopoietic Malignancies in Allograft Kidneys: Where Does the Tumorigenesis Begin?
Melika Kooshki Forooshani1, Fabiana Furci2, Akanksha Sharma3
1Department of Pathology, Rush University Medical Center, Chicago, Illinois.
Abstract:
Posttransplant malignancy is one of the major complications in patients who have received solid-organ transplants. Malignant cells can be donor transmitted, donor derived, or recipient derived. We undertook a retrospective study on tumors arising in allograft kidneys to elucidate their clinical and histological features and to determine the origin of tumor cells. Our pathology database (2002-2022) was searched for allograft kidneys with nonhematopoietic malignancies. Clinical information and histological features were reviewed. The short tandem repeat genotypes of tumor cells were compared with those of control tissue. Eight cases of allograft kidneys with nonhematopoietic malignancies were identified, including 5 men and 3 women, with a mean age of 55 (range 37-81) years. Histologically, there were 3 clear cell renal cell carcinomas, 2 high-grade urothelial carcinomas of the renal pelvis, 2 papillary renal cell carcinomas, and 1 squamous cell carcinoma. All patients had tumors confined to the allograft kidneys. The short tandem repeat genotyping showed that the tumor cells were of donor origin in all cases. In our study, development of nonhematopoietic malignancies in allograft kidneys was very rare, with an incidence of about 0.53%. The most common histological subtype was clear cell renal cell carcinomas. All the tumors were of donor origin. Given the long interval (average 16.6 years) between kidney transplant and allograft nephrectomy, it is more likely that the tumor started de novo in the allograft kidneys after transplant (donor derived), and not from carryover donor tumor cells (donor transmitted). In addition, all patients had organ-confined disease and not widespread metastasis, which also favors de novo tumorigenesis in the allograft kidneys. Therefore, in donors without a history of malignancy, changing the current practice of donor screening to detect possible circulating tumor cells and to eliminate carryover is unlikely to be beneficial.
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction

